Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Karunaratna, Nathasha
Jensen, Andrew
Wong, Shirley
Shapiro, Julia
Weickhardt, Andrew
Spain, Lavinia
Azad, Arun
Kwan, Edmond M.
Muthusamy, Arun
Torres, Javier
Parente, Phillip
Parnis, Francis
Goh, Jeffrey
Gibbs, Peter
Tran, Ben
Anton, Angelyn
机构：
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs47
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [1] Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Jensen, A.
    Karunaratna, N.
    Wong, S.
    Shapiro, J.
    Weickhardt, A.
    Spain, L.
    Azad, A. A.
    Kwan, E.
    Muthusamy, A.
    Torres, J.
    Parente, P.
    Francis, P.
    Parnis, F. X.
    Goh, J.
    Gibbs, P.
    Tran, B.
    Anton, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1329 - S1330
  • [2] FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Zukotynski, Katherine A.
    Jadvar, Hossein
    Cho, Steve Y.
    Kim, Chun Ki
    Cline, Kathryn
    Emmenegger, Urban
    Hotte, Sebastien J.
    Pond, Gregory Russell
    Winquist, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).
    Pouliot, Frederic
    Saad, Fred
    Rousseau, Etienne
    Richard, Patrick O.
    Zamanian, Atefeh
    Probst, Stephan
    Levesque, Eric
    Castonguay, Vincent
    Marcoux, Nicolas
    Juneau, Daniel
    Lodde, Michele
    Lattouf, Jean-Baptiste
    Buteau, Francois-Alexandre
    Hamilou, Zineb
    Pavic, Michel
    Castilloux, Jean-Francois
    Bouvet, Guillaume
    Tetu, Amelie
    Guerin, Brigitte
    Beauregard, Jean-Mathieu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 31 - 31
  • [4] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Bilusic, Marijo
    Karzai, Fatima
    Cordes, Lisa M.
    Strauss, Julius
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Karzai, Fatima
    Cordes, Lisa M.
    Schlom, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] Treatment response evaluation with PSMA-PET/CT imaging in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Kleiburg, F.
    De Geus-Oei, L. F.
    Luelmo, S. A. C.
    Spijkerman, R.
    Toonen, F. A. J.
    Smit, F.
    Van der Hulle, T.
    Heijmen, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S540 - S540
  • [7] BURDEN OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN TURKEY
    Erdal, E.
    Malhan, S.
    Oksuz, E.
    Benekli, M.
    Cag, C.
    Dane, F.
    Kabasakal, L.
    Kucuk, O.
    Sozen, T. S.
    Sar, C.
    Kahveci, B.
    VALUE IN HEALTH, 2016, 19 (07) : A725 - A726
  • [8] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [9] Testosterone levels in metastatic castration-resistant prostate cancer (mCRPC).
    von Klot, Christoph A. J.
    Boeker, Alena
    Herrmann, Thomas R. W.
    Kramer, Mario W.
    Kuczyk, Markus A.
    Merseburger, Axel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [10] FAPI, PSMA and FDG PET/CT in patients with advanced metastatic castration-resistant prostate cancer (mCRPC): a triple tracer comparison
    Pabst, K. M.
    Fendler, W. P.
    Hadaschik, B.
    Kesch, C.
    Hirmas, N.
    Kessler, L.
    Gruenwald, V.
    Hamacher, R.
    Nader, M.
    Berliner, C.
    Umutlu, L.
    Puellen, L.
    Herrmann, K.
    Lueckerath, K.
    Castellucci, P.
    Fanti, S.
    Mei, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S118 - S119
12345